| IPI00027847 - LPL, LIPOPROTEIN LIPASE PRECURSOR. | |
|---|---|
| Uniprot Accession: Q8NEW3 | |
| Uniprot ID: Q8NEW3_HUMAN | |
| Mapping: Chr 8, 19841232 - 19867912 | |
| Entrez Gene: 4023 | |
| Entrez MapView: |
|
| +All IPI Database Cross References | |
| IPI records in this ortholog cluster (Cluster: MGI_ORTHOLOGY_12726) |
|---|
| Rat: Lpl, LIPOPROTEIN LIPASE PRECURSOR. |
| Mouse: Lpl, LIPOPROTEIN LIPASE PRECURSOR. |
| Mouse: Lpl, LIPOPROTEIN LIPASE. |
| Human: LPL, LIPOPROTEIN LIPASE PRECURSOR. |
| GO Term | Aspect | Human | Mouse | Rat |
|---|---|---|---|---|
| membrane | C | IEA | IEA | IEA |
| extracellular space | C | RCA | ISS | |
| extracellular matrix | C | IDA | ||
| extracellular region | C | TAS | ISS | |
| chylomicron | C | IEA | IEA | IEA |
| hydrolase activity | F | IEA | IEA | IEA |
| GPI anchor binding | F | IEA | IEA | IEA |
| triglyceride binding | F | IDA | ||
| lipoprotein lipase activity | F | TAS | IDA | IDA ISS IDA IEA |
| heparin binding | F | TAS | IEA | ISS IEA |
| lipid transporter activity | F | IEA | IEA | IEA |
| catalytic activity | F | IEA | ||
| fatty acid metabolic process | P | NR | ISS | |
| lipid metabolic process | P | IEA | ||
| lipid catabolic process | P | IEA | IEA | IDA IEA |
| triacylglycerol biosynthetic process | P | IMP | ||
| circulation | P | TAS | ISS |
| GO Graph Color Key: | Rat | Mouse | Human | Rat & Mouse | Mouse & Human | Rat & Human | Rat, Mouse & Human |
SVG image
| GO Graph Color Key: | Rat | Mouse | Human | Rat & Mouse | Mouse & Human | Rat & Human | Rat, Mouse & Human |
SVG image
| GO Graph Color Key: | Rat | Mouse | Human | Rat & Mouse | Mouse & Human | Rat & Human | Rat, Mouse & Human |
SVG image
| MP Term | Aspect | Human | Mouse | Rat |
|---|---|---|---|---|
| skin/coat/nails phenotype | MP | Un | ||
| adipose tissue phenotype | MP | Un | ||
| liver/biliary system phenotype | MP | Un | ||
| homeostasis/metabolism phenotype | MP | Un Un Un | ||
| lethality-embryonic/perinatal | MP | Un Un | ||
| muscle phenotype | MP | Un Un | ||
| life span-post-weaning/aging | MP | Un | ||
| cardiovascular system phenotype | MP | Un Un Un | ||
| respiratory system phenotype | MP | Un Un | ||
| increased circulating free fatty acid level | N | ISS | ||
| muscular atrophy | N | ISS | ||
| premature death | N | ISS | ||
| decreased circulating triglyceride level | N | ISS | ||
| weight loss | N | ISS | ||
| myopathy | N | ISS |
| DO Term | Aspect | Human | Mouse | Rat |
|---|---|---|---|---|
| Hypertriglyceridemia | D | ISS | ||
| Diabetes Mellitus, Non-Insulin-Dependent | D | ISS | ||
| Lipoprotein Lipase Deficiency, Familial | D | ISS | ||
| Coronary Arteriosclerosis | D | ISS | ||
| Hypertension | D | ISS |
| PW Term | Aspect | Human | Mouse | Rat |
|---|---|---|---|---|
| lipid metabolic pathway | W | ISS | ||
| glycerolipid metabolic pathway | W | IEA | ||
| Alzheimer disease pathway | W | IEA | ||
| lipoprotein metabolic pathway | W | ISS |
| KEGG Pathway | Human | Mouse | Rat |
|---|---|---|---|
| Alzheimer's disease (05010) | Present in KEGG pathway | Present in KEGG pathway | Present in KEGG pathway |
| PPAR signaling pathway (03320) | Present in KEGG pathway | Present in KEGG pathway | Present in KEGG pathway |
| Glycerolipid metabolism (00561) | Present in KEGG pathway | Present in KEGG pathway | Present in KEGG pathway |